ROG.VX: FDA Label-Ocrevus ineffective in women with breast cancer risk

Despite ROG last week’s Ocrevus FDA approval for PPMS & RRMS, its lack of benefit in women with PPMS and increased cancer risk and little differentiation in RRMS leaves consensus at risk